New drug launches, hand-in-hand cooperation to improve accessibility... Good news continues in the field of diabetes medications

【Pharmaceutical Network Industry News】 The field of diabetes treatment has always been one of the hot spots in the global pharmaceutical field, and in recent years, with the acceleration of the global aging process and the change of people's lifestyle, the number of diabetic patients has also increased
.
According to the World Health Organization (WHO), 200-300 million people worldwide will develop type 2 diabetes by 2025
.
According to the 2020 Report on Nutrition and Chronic Diseases of Chinese Residents, the prevalence of diabetes among adults in China is 11.
9%, with about 125 million diabetics
.
Therefore, it is important to
strengthen the development of diabetes drugs and improve access to drugs, so that classic antidiabetic drugs can benefit more hospitals and patients.
It is reported that in the field of drug research and development, there has been good news in China recently, that is, on October 8, the State Medical Products Administration approved the marketing of Dougliptin tablets (trade name: Huatang Ning), a Class 1 innovative drug declared by Hua Medicine, which can be combined with diet control and exercise to improve blood sugar control
in adult patients with type 2 diabetes.
Combined with metformin hydrochloride: When metformin hydrochloride alone is poorly controlled, it can be used in combination with metformin hydrochloride to improve blood glucose control
in adult patients with type 2 diabetes mellitus with diet and exercise.
Docagliatin tablets are self-developed hypoglycemic drugs in China, which can improve the glucose-stimulated insulin secretion phase of patients with type 2 diabetes, improve the islet β cell function index, insulin early secretion index and glucose disposal index, reduce insulin resistance index, reduce blood sugar (postprandial blood glucose and fasting blood sugar), and control the patient's 24-hour blood glucose level
.
The industry said that the launch of docagliatin tablets is expected to change the treatment mode of diabetes, bring new choices to diabetics, and meet the needs
of more diabetic patients.
In addition, there has been good news in recent days in terms of improving access to
medicines.
That is, on the evening of November 11, BAHEAL Pharmaceutical issued an announcement that the company recently signed a strategic cooperation agreement
with AstraZeneca China.
According to the agreement, BAHEAL Pharmaceutical will obtain the commercial operation rights
of AstraZeneca's hypoglycemic drug Anritze ® (saxagliptin tablets).
The two parties hope that through this cooperation, access to drugs will be further improved, so that classic antidiabetic drugs can benefit more hospitals and patients
.
BAHEAL Pharmaceutical said that as a third-party commercialization platform with commercialization capabilities, it will further enhance Anritzer's development space
in the Chinese market with its professional operation and digital marketing capabilities.
AstraZeneca China expressed its hope that the two sides will work closely together on the basis of mutual trust and explore innovative cooperation models to maximize the long-term value of Anritzer and benefit more diabetic patients
.
For this cooperation, some industry insiders analyzed that the two parties will give full play to the expertise and advantages of multinational pharmaceutical companies and local third-party commercialization platforms in their respective fields to provide patients with better medical and health products and services and promote the continuous development of
the health industry.
Nowadays, with the improvement of people's living standards, the prevalence of diabetes continues to rise, and the demand for related drugs is also expanding, according to Frost & Sullivan's statistics, China's diabetes drug market size is expected to be 103.
8 billion yuan in 2022, and is expected to reach 259.
2 billion yuan in 2030, with a CAGR of up to 11.
9%.

The global diabetes drug market is expected to grow to $90.
2 billion by 2025 and $109.
1 billion by 2030.

It can be seen that the market prospect of diabetes drugs is very broad
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.